These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 19200020)

  • 1. Natural product inhibitors of Hsp90: potential leads for drug discovery.
    Amolins MW; Blagg BS
    Mini Rev Med Chem; 2009 Feb; 9(2):140-52. PubMed ID: 19200020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule inhibitors targeting heat shock protein 90: An updated review.
    Li Y; Dong J; Qin JJ
    Eur J Med Chem; 2024 Sep; 275():116562. PubMed ID: 38865742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural heat shock protein 90 inhibitors in cancer and inflammation.
    Costa TEMM; Raghavendra NM; Penido C
    Eur J Med Chem; 2020 Mar; 189():112063. PubMed ID: 31972392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside?
    Khandelwal A; Crowley VM; Blagg BSJ
    Med Res Rev; 2016 Jan; 36(1):92-118. PubMed ID: 26010985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy.
    Franke J; Eichner S; Zeilinger C; Kirschning A
    Nat Prod Rep; 2013 Oct; 30(10):1299-323. PubMed ID: 23934201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Design, Synthesis and In Vitro Evaluation of Substituted Benzofurans as Hsp90 Inhibitors.
    Kadasi S; Costa TEMM; Arukala N; Toshakani M; Duggineti C; Thota S; Dutta Gupta S; Raj S; Penido C; Henriques MG; Raghavendra NM
    Med Chem; 2018; 14(1):44-52. PubMed ID: 28641528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer.
    Neckers L
    Curr Top Med Chem; 2006; 6(11):1163-71. PubMed ID: 16842153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purine-scaffold Hsp90 inhibitors.
    Taldone T; Chiosis G
    Curr Top Med Chem; 2009; 9(15):1436-46. PubMed ID: 19860732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent update on discovery and development of Hsp90 inhibitors as senolytic agents.
    Dutta Gupta S; Pan CH
    Int J Biol Macromol; 2020 Oct; 161():1086-1098. PubMed ID: 32561284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural compounds as potential Hsp90 inhibitors for breast cancer-Pharmacophore guided molecular modelling studies.
    Rampogu S; Parate S; Parameswaran S; Park C; Baek A; Son M; Park Y; Park SJ; Lee KW
    Comput Biol Chem; 2019 Dec; 83():107113. PubMed ID: 31493740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based and in silico design of Hsp90 inhibitors.
    Sgobba M; Rastelli G
    ChemMedChem; 2009 Sep; 4(9):1399-409. PubMed ID: 19685544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ansamycin inhibitors of Hsp90: nature's prototype for anti-chaperone therapy.
    Porter JR; Ge J; Lee J; Normant E; West K
    Curr Top Med Chem; 2009; 9(15):1386-418. PubMed ID: 19860734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and development of pyrazole-scaffold Hsp90 inhibitors.
    McDonald E; Jones K; Brough PA; Drysdale MJ; Workman P
    Curr Top Med Chem; 2006; 6(11):1193-203. PubMed ID: 16842156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat shock protein 90 inhibitors as therapeutic agents.
    Gomez-Monterrey I; Sala M; Musella S; Campiglia P
    Recent Pat Anticancer Drug Discov; 2012 Sep; 7(3):313-36. PubMed ID: 22338602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances in the Discovery of Novel HSP90 Inhibitors: An Update from 2014.
    Xiao Y; Liu Y
    Curr Drug Targets; 2020; 21(3):302-317. PubMed ID: 31465284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An updated patent review of anticancer Hsp90 inhibitors (2013-present).
    Li L; Chen NN; You QD; Xu XL
    Expert Opin Ther Pat; 2021 Jan; 31(1):67-80. PubMed ID: 32990109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site.
    Hadden MK; Lubbers DJ; Blagg BS
    Curr Top Med Chem; 2006; 6(11):1173-82. PubMed ID: 16842154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors.
    Zhao H; Garg G; Zhao J; Moroni E; Girgis A; Franco LS; Singh S; Colombo G; Blagg BS
    Eur J Med Chem; 2015 Jan; 89():442-66. PubMed ID: 25462258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone.
    Workman P
    Cancer Detect Prev; 2002; 26(6):405-10. PubMed ID: 12507224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.
    Brandt GE; Blagg BS
    Curr Top Med Chem; 2009; 9(15):1447-61. PubMed ID: 19860731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.